423 related articles for article (PubMed ID: 30181581)
21. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
22. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
Karschnia P; Jordan JT; Forst DA; Arrillaga-Romany IC; Batchelor TT; Baehring JM; Clement NF; Gonzalez Castro LN; Herlopian A; Maus MV; Schwaiblmair MH; Soumerai JD; Takvorian RW; Hochberg EP; Barnes JA; Abramson JS; Frigault MJ; Dietrich J
Blood; 2019 May; 133(20):2212-2221. PubMed ID: 30808634
[TBL] [Abstract][Full Text] [Related]
23. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Neelapu SS; Tummala S; Kebriaei P; Wierda W; Gutierrez C; Locke FL; Komanduri KV; Lin Y; Jain N; Daver N; Westin J; Gulbis AM; Loghin ME; de Groot JF; Adkins S; Davis SE; Rezvani K; Hwu P; Shpall EJ
Nat Rev Clin Oncol; 2018 Jan; 15(1):47-62. PubMed ID: 28925994
[TBL] [Abstract][Full Text] [Related]
24. [Practical aspects of the application of CAR T cells and management of their toxicities].
Bücklein V; Blumenberg V; Subklewe M
Dtsch Med Wochenschr; 2021 Sep; 146(17):1129-1137. PubMed ID: 34448189
[TBL] [Abstract][Full Text] [Related]
25. Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.
Geyer MB; Brentjens RJ
Cytotherapy; 2016 Nov; 18(11):1393-1409. PubMed ID: 27592405
[TBL] [Abstract][Full Text] [Related]
26. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia.
Liu Y; Chen X; Han W; Zhang Y
Drugs Today (Barc); 2017 Nov; 53(11):597-608. PubMed ID: 29451276
[TBL] [Abstract][Full Text] [Related]
27. Advances in CAR T Therapy for Hematologic Malignancies.
Freyer CW; Porter DL
Pharmacotherapy; 2020 Aug; 40(8):741-755. PubMed ID: 32383222
[TBL] [Abstract][Full Text] [Related]
28. Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities.
Rubinstein JD; Nelson AS; Krupski C; O'Brien W; Taylor JM; Badgett TC; Huang M; Davies SM; Phillips CL
Pediatr Blood Cancer; 2020 Apr; 67(4):e28199. PubMed ID: 32020723
[TBL] [Abstract][Full Text] [Related]
29. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
30. Neurological toxicities and coagulation disorders in the cytokine release syndrome during CAR-T therapy.
Mei H; Jiang H; Wu Y; Guo T; Xia L; Jin R; Hu Y
Br J Haematol; 2018 Jun; 181(5):689-692. PubMed ID: 28369673
[No Abstract] [Full Text] [Related]
31. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
[TBL] [Abstract][Full Text] [Related]
32. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
33. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
34. Management of cytokine release syndrome related to CAR-T cell therapy.
Chen H; Wang F; Zhang P; Zhang Y; Chen Y; Fan X; Cao X; Liu J; Yang Y; Wang B; Lei B; Gu L; Bai J; Wei L; Zhang R; Zhuang Q; Zhang W; Zhao W; He A
Front Med; 2019 Oct; 13(5):610-617. PubMed ID: 31571160
[TBL] [Abstract][Full Text] [Related]
35. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.
Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T
Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090
[TBL] [Abstract][Full Text] [Related]
36. Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy.
Luo H; Wang N; Huang L; Zhou X; Jin J; Li C; Wang D; Xu B; Xu J; Jiang L; Wang J; Cao Y; Xiao Y; Zhang Q; Mao X; Liu S; Chen L; Xiao M; Zhou J
J Immunother Cancer; 2019 Oct; 7(1):271. PubMed ID: 31640816
[TBL] [Abstract][Full Text] [Related]
37. Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy.
Liu Y; Chen X; Wang D; Li H; Huang J; Zhang Z; Qiao Y; Zhang H; Zeng Y; Tang C; Yang S; Wan X; Chen YH; Zhang Y
J Immunother; 2018; 41(9):406-410. PubMed ID: 30198955
[TBL] [Abstract][Full Text] [Related]
38. Optimizing the Clinical Impact of CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia: Looking Back While Moving Forward.
Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
Front Immunol; 2021; 12():765097. PubMed ID: 34777381
[TBL] [Abstract][Full Text] [Related]
39. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.
Thomas X; Paubelle E
Expert Opin Biol Ther; 2018 Nov; 18(11):1095-1106. PubMed ID: 30296188
[TBL] [Abstract][Full Text] [Related]
40. [Not Available].
Dourthe MÉ; Yakouben K; Chaillou D; Lesprit E; Dalle JH; Baruchel A
Bull Cancer; 2018 Dec; 105 Suppl 2():S147-S157. PubMed ID: 30686353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]